# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0193 |
| Population Package | PP-0193 |
| Title | Endoscopic Resection for Early Gastric Cancer |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |
| QA Standard | Four-layer Gold QA |
| Decision Status | APPROVED / LOCKED |

---

# QA Objective

This QA review verifies that PP-0193:

1. follows the approved and locked Decision Batch;
2. conforms to the Gold Population Package Specification;
3. preserves the required Gold depth;
4. uses the project Source Materials as the clinical evidence base;
5. maintains clear ownership boundaries with adjacent Population Packages;
6. provides patient-facing clinical education without individualized treatment advice;
7. contains the required Knowledge Graph;
8. maintains evidence traceability;
9. contains exactly the four required Gold artifacts;
10. is ready for integration.

---

# Layer 1 — Content QA

## 1.1 Scope Compliance

### PASS

The package answers one atomic clinical question:

> **When can endoscopic resection be used to treat early gastric cancer, and how is its curative role determined?**

The content remains centered on:

- ER strategy;
- patient/lesion selection;
- depth;
- nodal risk;
- pathology;
- curative assessment;
- ER versus surgery;
- downstream surveillance/additional treatment interface.

No major off-scope expansion was identified.

---

## 1.2 Completeness

### PASS

The CKO covers:

- definition;
- patient explanation;
- clinical importance;
- selection concepts;
- depth;
- lymph-node risk;
- histology;
- size;
- ulceration;
- LVI;
- pre-ER assessment;
- EUS interface;
- EMR versus ESD;
- ESD preference;
- complete/en-bloc resection;
- specimen pathology;
- curative/non-curative assessment;
- surgery interface;
- expertise;
- procedural risks;
- surveillance;
- misconceptions;
- patient questions;
- key messages;
- Knowledge Graph.

---

## 1.3 Internal Consistency

### PASS

The same ownership logic is maintained across all four artifacts:

**ER strategy**

↓

**EMR / ESD modality-specific knowledge**

↓

**post-ER pathology**

↓

**curative/non-curative assessment**

↓

**surveillance / additional management**

No contradictory ownership statement was identified.

---

## 1.4 Artifact Structure

### PASS

Required artifacts are present:

1. 01_CKO.md
2. 02_KNOWLEDGE_PASSPORT.md
3. 03_PRIMARY_EVIDENCE_PACKAGE.md
4. 04_QA_REPORT.md

No additional markdown artifact is included in the Gold package.

---

# Layer 2 — Clinical QA

## 2.1 Evidence Grounding

### PASS

The clinical content is grounded primarily in:

- NCCN Gastric Cancer v2.2026;
- NCI Gastric Cancer Treatment PDQ;
- project pathology/staging materials;
- project patient-facing gastric-cancer materials where relevant.

The package does not depend on unsupported general medical assertions for its core claims.

---

## 2.2 Guideline Consistency

### PASS

The package is consistent with the source-supported framework that:

- ER is used for selected early gastric cancers;
- Tis/T1a disease is central to the ER framework;
- ER includes EMR and ESD;
- ESD is preferred in the current NCCN framework;
- curative assessment requires integrated specimen pathology;
- post-ER surveillance is required.

---

## 2.3 Clinical Safety

### PASS

The package avoids individualized treatment recommendations.

It does not tell a patient:

- that they personally qualify for ER;
- that they personally should receive ESD;
- that they personally should avoid surgery;
- that a particular pathology result mandates a specific treatment.

Instead it explains the decision factors and directs individualized decisions to the treating team.

---

## 2.4 Risk Communication

### PASS

The package does not present:

- simplified universal eligibility rules;
- unsupported numerical risk estimates;
- guaranteed outcomes;
- universal claims that ESD is always superior;
- negative-margin status as the sole definition of cure.

---

## 2.5 Curative / Non-Curative Terminology

### PASS

The package correctly treats curative status as an integrated pathologic and clinical assessment rather than a single procedural endpoint.

It also avoids describing non-curative ER as a procedural failure.

---

## 2.6 ER Versus Surgery

### PASS

The package explains the distinction at strategic level without reproducing a detailed gastrectomy algorithm.

---

## 2.7 Procedural Risk

### PASS

Bleeding and perforation are acknowledged at a high level.

Detailed complication-management instructions are intentionally excluded.

---

# Layer 3 — Educational QA

## 3.1 Patient-Facing Language

### PASS

Medical terminology is introduced with explanation.

Examples include:

- endoscopic resection;
- EMR;
- ESD;
- Tis/T1a/T1b;
- lymphovascular invasion;
- en-bloc resection;
- curative/non-curative resection.

---

## 3.2 Logical Flow

### PASS

The package follows a clinically intuitive sequence:

**What ER is**

↓

**Why it can work**

↓

**Who may be suitable**

↓

**Why depth/nodal risk matter**

↓

**How EMR/ESD differ**

↓

**What pathology determines**

↓

**Curative versus non-curative**

↓

**What happens next**

↓

**Follow-up**

This supports patient comprehension.

---

## 3.3 Misconception Handling

### PASS

The package explicitly addresses common high-risk misunderstandings:

- early cancer = automatically ER-eligible;
- ER = biopsy;
- ESD = always better;
- removal = treatment finished;
- negative margins = automatically curative;
- non-curative = failed procedure;
- ER = no future surgery;
- ER = no follow-up.

---

## 3.4 Patient Questions

### PASS

Questions are included to support shared decision-making without providing individualized recommendations.

---

## 3.5 Depth

### PASS — GOLD DEPTH

The package preserves the project's absolute Gold-depth standard.

It does not:

- compact;
- shorten;
- summarize away substantive reasoning;
- collapse the Knowledge Graph;
- reduce evidence detail;
- reduce QA detail;
- reduce patient-facing explanation.

The structure follows the approved Gold references and the project Gold Population Package Specification.

---

# Layer 4 — Governance QA

## 4.1 Source-First Compliance

### PASS

The package was produced using the project Source Files as the evidence basis.

Governance sources were used for:

- structure;
- workflow;
- package identity;
- boundary;
- artifact requirements.

Clinical claims were grounded in the relevant clinical source materials.

---

## 4.2 Locked Decision Compliance

### PASS

The approved PP-0193 Decision Batch is treated as locked.

No substantive scope decision was reopened during production.

---

## 4.3 Gold Specification Compliance

### PASS

The package conforms to the required four-artifact structure and includes:

- CKO;
- Knowledge Passport;
- Primary Evidence Package;
- QA Report.

---

## 4.4 Knowledge Graph Compliance

### PASS

The package contains:

- Prerequisite PP;
- Related PP;
- Next / Downstream PP.

The graph is consistent with the ER strategy → modality → pathology → downstream management architecture.

---

## 4.5 Boundary Compliance

### PASS

The production Boundary is expressed in the required four-part ownership model:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

The boundary is concise, ownership-oriented, non-duplicative and clinically meaningful.

---

## 4.6 Versioning

### PASS

Semantic version:

**1.0.0**

is used consistently across artifacts.

---

## 4.7 Repository Readiness

### PASS

The package contains exactly four markdown artifacts and is packaged as one ZIP.

---

# Adjacent-Package Overlap QA

## Upstream

### Endoscopy / Biopsy / EUS / Staging

PP-0193 uses these only as prerequisites and interfaces.

It does not reproduce their detailed methodology.

### Pathology

PP-0193 uses pathology to explain curative assessment but does not duplicate detailed pathology interpretation.

---

## Adjacent

### EMR

PP-0193 owns:

- why/when ER is considered;
- the strategic role of EMR.

Dedicated EMR content owns:

- detailed EMR technique.

### ESD

PP-0193 owns:

- why/when ESD is considered;
- why ESD is preferred in the NCCN framework.

Dedicated ESD content owns:

- detailed ESD technique.

---

## Downstream

### Surgery

PP-0193 owns the transition:

**non-curative / unsuitable ER → consideration of additional treatment**

Surgical packages own:

- operation selection;
- gastrectomy;
- lymphadenectomy;
- surgical technique.

### Surveillance

PP-0193 explains why surveillance is needed.

Dedicated surveillance packages own:

- detailed schedules;
- recurrence monitoring;
- detailed follow-up algorithms.

---

# Evidence Traceability QA

## Major Claims Traceable to Source Set

### ER as a treatment option

Traceable to:

- NCCN Gastric Cancer v2.2026.
- NCI Gastric Cancer Treatment PDQ.

### EMR/ESD framework

Traceable to:

- NCCN Gastric Cancer v2.2026.

### ESD preference

Traceable to:

- NCCN Gastric Cancer v2.2026.

### Nodal-risk rationale

Traceable to:

- NCI Gastric Cancer Treatment PDQ.

### Curative assessment

Traceable to:

- NCCN Gastric Cancer v2.2026.

### Surveillance

Traceable to:

- NCCN Gastric Cancer v2.2026.

No major clinical claim is intentionally presented as a guideline-supported fact without an identified project source.

---

# Evidence Gap QA

### PASS

Known evidence limitations are explicitly acknowledged.

The package does not attempt to manufacture:

- a universal eligibility calculator;
- universal procedural risk estimates;
- individualized treatment recommendations;
- detailed expanded-indication rules beyond the source-supported conceptual level.

---

# Patient-Safety QA

### PASS

The package avoids:

- individualized diagnosis;
- individualized treatment;
- unsupported certainty;
- procedural instructions;
- emergency medical claims outside scope;
- false reassurance.

---

# Gold Artifact Completeness Check

| Artifact | Present | Structural QA | Depth QA |
|---|---|---|---|
| 01_CKO.md | PASS | PASS | PASS — GOLD |
| 02_KNOWLEDGE_PASSPORT.md | PASS | PASS | PASS — GOLD |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | PASS | PASS | PASS — GOLD |
| 04_QA_REPORT.md | PASS | PASS | PASS — GOLD |

---

# Final Quality Decision

# PASS

PP-0193 satisfies the locked **FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1**, the applicable **CORE_WORKING_RULES v1.7**, the approved/locked PP-0193 Decision Batch, and the project's absolute Gold-depth rule.

The package maintains the intended architecture:

**Early Gastric Cancer**

↓

**PP-0193 — Endoscopic Resection for Early Gastric Cancer**

↓

**EMR / ESD Modality-Specific Packages**

↓

**Post-ER Pathology**

↓

**Curative vs Non-Curative Assessment**

↓

**Surveillance / Additional Treatment**

The package does not duplicate substantive ownership of:

- detailed EMR technique;
- detailed ESD technique;
- pathology methodology;
- EUS/staging methodology;
- gastrectomy/lymphadenectomy;
- systemic treatment;
- detailed surveillance;
- recurrence management.

---

# Reviewer Notes

PP-0193 functions as a **treatment-strategy bridge node** for selected early gastric cancer.

Its principal value is to explain why endoscopic treatment can sometimes replace gastrectomy, while preserving the oncologic logic that makes patient selection essential.

The package deliberately avoids the unsafe simplifications:

1. **Early cancer → automatically eligible for ER.**
2. **Small lesion → automatically curative.**
3. **ESD → universally better for every lesion.**
4. **Removal → treatment completed.**
5. **Negative margin → automatically curative.**
6. **Non-curative ER → procedural failure.**

The package instead preserves the clinically appropriate sequence:

**selection → resection → pathology → curative assessment → surveillance/additional management.**

---

# Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
